Funding profile · AI care delivery

Akido

One Form D on file under the company’s own name, reporting 40 percent more money than the press release announced. Two single-company vehicles add $8.2 million from 86 further investors.

$84.3MSold and closed, Form D of May 16, 2025
$60.0MSeries B as announced the day before
94Investors, average about $896,000 each
$8.2MRaised by two Akido SPVs, 2025

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2015 Y Combinator, Winter 2015 Not disclosed Y Combinator YC data
2015 to 2024 Earlier private rounds Not disclosed Y Combinator, Future Communities Capital, Jeff Dean, Comprehensive Blood and Cancer Center Company release
Mar to May 2025 Series B $60.0M announced · $84,254,689 sold per Form D Led by Oak HC/FT, with Greco and SNR Filing exceeds release
Mar to Oct 2025 SPV: Jack Greco – Akido, LLC $7,950,000 72 · SaaS Ventures, L.L.C. and Brian Gaister Form D
Jun to Jul 2025 SPV: NV Akido, a series of NDSPV Investments, LP $246,285 14 · Necessary Ventures Form D
To date Reported cumulative Over $100M Not itemized Reported
All years Federal grants None found NIH, NSF Not found

What the filings show

Akido Labs, Inc. · Form D · filed May 16, 2025

First sale
Mar 11, 2025
Offered
$84,254,689 equity
Sold
$84,254,689 · $0 remaining
Investors
94 · average about $896,326
Exemption
Rule 506(b), no non-accredited investors
Related persons
Prashant Samant and Jared Goodner (executive officer, director, promoter); Andrew Adams, Rohit Gupta, John Greco and Prasad Jeereddi (directors)
Filing
SEC EDGAR, CIK 0002063139, Delaware corporation, Los Angeles

Jack Greco – Akido, LLC · Form D · filed Oct 29, 2025

First sale
Mar 26, 2025
Type
Pooled investment fund, venture capital fund
Offered
Indefinite
Sold
$7,950,000
Investors
72 · average about $110,417
Exemptions
Rule 506(b); Investment Company Act 3(c)(1) and 3(c)(7)
Related persons
SaaS Ventures, L.L.C. (member of the issuer); Brian Gaister (executive officer)
Filing
SEC EDGAR, CIK 0002069688, Delaware LLC formed 2025, Coral Gables FL

NV Akido, a series of NDSPV Investments, LP · Form D · filed Jul 17, 2025

First sale
Jun 26, 2025
Type
Pooled investment fund, venture capital fund
Sold
$246,285 of $246,285 · $0 remaining
Investors
14 · average about $17,592 · $1,000 minimum
Exemptions
Rule 506(b); Investment Company Act 3(c)(1)
Related persons
Necessary Ventures GP I LLC (general partner); Neil Devani (manager of the general partner)
Filing
SEC EDGAR, CIK 0002058949, Delaware LP formed 2025, Los Angeles

Reading the filings

  1. The filing is 40 percent larger than the announcement.Akido said $60 million on May 15, 2025. The Form D signed the next day reports $84,254,689 offered and the same amount sold, nothing remaining. The difference is $24,254,689. An offering reported closed at the full amount usually means earlier notes or safes converted into the priced round and were counted in it. Akido has not explained the gap and has filed no amendment.
  2. The checks are institutional.$84,254,689 divided by 94 investors is about $896,326 each. That is a venture round, not a crowd, and it had been open 66 days by the press release: first sale March 11, announcement May 15.
  3. The Form D was late.Regulation D requires the notice within 15 days of the first sale. First sale was March 11, 2025; the filing landed May 16, a day after the press release. The Greco vehicle was later still: first sale March 26, filed October 29, a gap of 217 days.
  4. A board seat shows up in the filing eight months before it was announced.The May 2025 Form D lists John Greco as a director. Akido announced on January 22, 2026 that Jack Greco had joined its board and was a major investor in the recent financing. The filing had him there already.
  5. Two vehicles were built to carry other people into the round.Jack Greco – Akido, LLC pooled $7,950,000 from 72 investors, about 9 percent of what the company reported selling. NV Akido, run by Necessary Ventures, pooled $246,285 from 14 investors at a $1,000 minimum. Together they moved $8,196,285 from 86 people absent from the company’s investor count.
  6. One EDGAR match is not this company.A fourth filer, TMF1 Akido LLC, appears in name searches. It is a Michigan LLC managed by Townsend Mertz, a Houston real estate private equity firm, unconnected to Akido the health company. Excluded here.
  7. Nothing has been filed since.No Form D appears under CIK 0002063139 after May 16, 2025, while the company went from 240 providers to more than 1,000. Either growth is funded from the Series B and revenue, or a later raise used Section 4(a)(2) and required no notice.

Commercial signals

Signal Detail Source type
Regulatory No FDA 510(k) or PMA record. Company position: clinicians make every final decision, so ScopeAI is decision support and exempt from device regulation. Public record
Network May 2025: 240 providers, 26 specialties, about 90 to 100 clinics, roughly 500,000 patients. July 2026: 100 clinics, more than 1,000 providers, 1 million patients in CA, NYC and RI. Company-stated
Revenue Grew 300 percent from 2024 to 2025. January 2026 release describes growth “into the mid-nine figures”. Unaudited and not in any filing. Company-stated
Payer mix Commercial, Medicare and Medicaid. Street medicine in Los Angeles and Kern County reported as 100 percent Medi-Cal funded. Company-stated
Acquisitions Chaparral Medical Group, Pomona, 2022. Controlling stake in Rhode Island Primary Care Physicians Corp, December 2023. Terms undisclosed. Independent
Clinical evidence No registered trial, no peer-reviewed ScopeAI paper, no published comparison with doctor-led visits. Not found

What to watch

  • An amended Form D reconciling the $60 million announcement with the $84,254,689 reported sold.
  • A Series C notice. Nothing has been filed under the company CIK since May 2025.
  • Any audited revenue figure. All current numbers are company-stated.
  • Regulatory exposure under California AB 489 and AB 3030, the main non-market risk to the model.

The Akido story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Candid Health: Shared investor: Oak Hc/Ft. Billing software built to get a medical claim right before it ever leaves the clinic, now sold to more than 200 provider organizations
  • H1: Also in Healthcare IT. A New York company that keeps a profile of roughly every doctor on earth and sells it to pharma, health insurers and now AI developers
  • The Human Diagnosis Project: Also in Healthcare IT. An open platform where doctors solve one another’s cases, built to hand specialist expertise to clinics that cannot buy it
  • Glass Health: Also in Healthcare IT. An AI tool that reads a one paragraph patient summary and returns a ranked differential diagnosis, now sold alongside an ambient scribe

Sources

  1. Public recordForm D, Akido Labs, Inc.SEC · May 16, 2025
  2. Public recordForm D, Jack Greco – Akido, LLCSEC · Oct 29, 2025
  3. Public recordForm D, NV Akido, a series of NDSPV Investments, LPSEC · Jul 17, 2025
  4. Public recordFDA 510(k), PMA and ClinicalTrials.gov: no Akido recordSearched Sep 22, 2026
  5. IndependentAkido Labs launches Bay Area street medicine programFierce Healthcare · Jan 2026
  6. IndependentAkido Labs And The Coming Shift To AI-Enabled MedicineForbes · Dec 2025
  7. IndependentThis medical startup uses LLMs to run appointmentsMIT Technology Review · Sep 2025
  8. IndependentNeil Devani partner page listing AkidoNecessary Ventures · accessed Sep 22, 2026
  9. CompanyAkido Raises $60 Million Series BBusiness Wire · May 15, 2025
  10. CompanyAkido Labs Strategic Leadership AppointmentsPR Newswire · Jan 22, 2026
  11. CompanyAkido Announces the First AI-Native Health SystemPR Newswire · Jul 2026
  12. InvestorThe Future of AI-Enabled HealthcareOak HC/FT · May 2025

Compiled from SEC, FDA and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in Akido. This page is not an offer to sell or a recommendation to buy any security.